National Institute of Public Health, Trubarjeva 2, 1000, Ljubljana, Slovenia.
Arch Public Health. 2012 Oct 24;70(1):24. doi: 10.1186/0778-7367-70-24.
Cancer is a major European public health issue and represents the second most important cause of death and morbidity in Europe. Moreover, as a result of constant advances in medicine, medical technology and other sciences, and due to improvements in economic circumstances, cancer survival rates are increasing in Europe and prevalent cases (i.e. number of subjects who have experienced cancer) represent a growing proportion of the population. In order to tackle cancer efficiently throughout the European Member states, the European Commission launched the Joint Action (JA) 'European Partnership for Action Against Cancer' (EPAAC) facilitated by the Community Health Programme, in September 2009. EPAAC is designed to fill a gap in cooperation, collaboration and shared experiences for countries with similar needs and diverse experience in the area of their national cancer control policies. Activities and studies are tackling the main challenges of cancer control in Europe as a whole and in the Member states, including the provision of services and health system responses, human resources and research. In contrast with previous European actions in the field of cancer, EPAAC joins different partners and stakeholders at various levels ranging from Member states (including Iceland and Norway) and Regions to patient representatives.
癌症是欧洲主要的公共卫生问题,也是欧洲第二大死亡和发病的主要原因。此外,由于医学、医疗技术和其他科学的不断进步,以及经济状况的改善,欧洲的癌症存活率正在提高,而常见病例(即经历过癌症的人数)在人口中所占比例越来越大。为了在整个欧洲成员国中有效地应对癌症,欧盟委员会于 2009 年 9 月通过社区卫生方案启动了联合行动(JA)“欧洲抗癌行动伙伴关系”(EPAAC)。EPAAC 的目的是填补在合作、协作和分享经验方面的空白,这些合作、协作和分享经验是为了有相似需求的国家提供服务和卫生系统应对措施、人力资源和研究。与欧洲以往在癌症领域的行动不同,EPAAC 将不同的合作伙伴和利益攸关方汇集在一起,涵盖了从成员国(包括冰岛和挪威)和地区到患者代表等各个层面。